Literature DB >> 21174574

Adiponectin levels in circulation and breast milk and mRNA expression in adipose tissue of preeclampsia women.

Yanhua Liu1, Lijun Zhu, Ya Pan, Lizhou Sun, Duan Chen, Xiaonan Li.   

Abstract

OBJECTIVE: Physiological insulin resistance occurs in normal pregnancy and is exaggerated in women with preeclampsia (PE). Adiponectin is a hormone with insulin-sensitizing, anti-atherogenic, and anti-inflammatory properties. Reports published on association between adiponectin levels and PE risk have been conflicting. This study sought to better determine the circulating adiponectin levels and its mRNA expression in adipose tissue in women with PE.
METHODS: This report includes a cross-sectional study at a Chinese clinical research center and meta-analysis. The cross-sectional study included normal pregnancy women (n = 28) and PE women (n = 20) who underwent cesarean operation. Adiponectin concentrations in maternal serum, cord blood, and colostrums were determined by ELISA. Adiponectin mRNA expression levels in adipose tissue were measured by quantitative real-time PCR. Meta-analysis was done on 13 studies, including 302 PE women and 385 normal pregnancy women.
RESULTS: In comparison with controls, PE women had higher serum adiponectin concentrations in maternal blood and breast milk, but lower adiponectin concentration in cord blood. Adiponectin mRNA expression in the subcutaneous (Sc) and omental adipose tissues (OM) did not differ between the two groups of women. Meta-analysis confirms that the circulating adiponectin levels were elevated in PE women (p < 0.01).
CONCLUSIONS: PE women had a higher adiponectin concentration in the maternal blood as well as breast milk but lower adiponectin concentration in umbilical cord blood when compared to women with normal pregnancy. The elevated circulating adiponectin levels in PE women are probably because of a reduced degradation/elimination rather than an increased synthesis of this hormone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21174574     DOI: 10.3109/10641955.2010.525273

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  5 in total

1.  Characterization of visceral and subcutaneous adipose tissue transcriptome in pregnant women with and without spontaneous labor at term: implication of alternative splicing in the metabolic adaptations of adipose tissue to parturition.

Authors:  Shali Mazaki-Tovi; Adi L Tarca; Edi Vaisbuch; Juan Pedro Kusanovic; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Zhong Dong; Sonia S Hassan; Roberto Romero
Journal:  J Perinat Med       Date:  2016-10-01       Impact factor: 1.901

2.  Different profile of serum leptin between early onset and late onset preeclampsia.

Authors:  Saeedeh Salimi; Farzaneh Farajian-Mashhadi; Anoosh Naghavi; Mojgan Mokhtari; Mahnaz Shahrakipour; Mohsen Saravani; Minoo Yaghmaei
Journal:  Dis Markers       Date:  2014-01-23       Impact factor: 3.434

3.  Characterization of Visceral and Subcutaneous Adipose Tissue Transcriptome and Biological Pathways in Pregnant and Non-Pregnant Women: Evidence for Pregnancy-Related Regional-Specific Differences in Adipose Tissue.

Authors:  Shali Mazaki-Tovi; Edi Vaisbuch; Adi L Tarca; Juan Pedro Kusanovic; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Zhong Dong; Sonia S Hassan; Roberto Romero
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

4.  Could a remarkable decrease in leptin and insulin levels from colostrum to mature milk contribute to early growth catch-up of SGA infants?

Authors:  Marina Nunes; Clécio Homrich da Silva; Vera Lucia Bosa; Juliana Rombaldi Bernardi; Isabel Cristina Ribas Werlang; Marcelo Zubaran Goldani
Journal:  BMC Pregnancy Childbirth       Date:  2017-12-06       Impact factor: 3.007

Review 5.  Adipose tissue function in healthy pregnancy, gestational diabetes mellitus and pre-eclampsia.

Authors:  Cara Trivett; Zoe J Lees; Dilys J Freeman
Journal:  Eur J Clin Nutr       Date:  2021-06-15       Impact factor: 4.016

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.